Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bavarian Nordic has exercised its option to extend the EBx embryonic stem cell line research license signed with Vivalis on March 30, 2007.
Subscribe to our email newsletter
The last 12 months collaboration allowed Bavarian Nordic to produce positive data, and to demonstrate that its recombinant vaccines platform, MVA-BN, can be efficiently and consistently manufacture with the EBx cell line.
Bavarian Nordic is evaluating the EBx cell line as a potential alternative production technology to its existing CEF process for the manufacturing of several vaccine candidates.
Franck Grimaud, Vivalis CEO said: “These results confirm again that the EBx platform turns to be the reference cell substrate for poxvirus based vaccines production and is relevant for a wide range of therapeutics applications. We are strongly convinced that more and more companies will move from eggs to the EBx cell line in a foreseeable future”.